These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 9784876)

  • 1. Discovering transthyretin amyloid fibril inhibitors by limited screening.
    Baures PW; Peterson SA; Kelly JW
    Bioorg Med Chem; 1998 Aug; 6(8):1389-401. PubMed ID: 9784876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibiting transthyretin conformational changes that lead to amyloid fibril formation.
    Peterson SA; Klabunde T; Lashuel HA; Purkey H; Sacchettini JC; Kelly JW
    Proc Natl Acad Sci U S A; 1998 Oct; 95(22):12956-60. PubMed ID: 9789022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rational design of potent human transthyretin amyloid disease inhibitors.
    Klabunde T; Petrassi HM; Oza VB; Raman P; Kelly JW; Sacchettini JC
    Nat Struct Biol; 2000 Apr; 7(4):312-21. PubMed ID: 10742177
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and evaluation of anthranilic acid-based transthyretin amyloid fibril inhibitors.
    Oza VB; Petrassi HM; Purkey HE; Kelly JW
    Bioorg Med Chem Lett; 1999 Jan; 9(1):1-6. PubMed ID: 9990446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clusterin regulates transthyretin amyloidosis.
    Lee KW; Lee DH; Son H; Kim YS; Park JY; Roh GS; Kim HJ; Kang SS; Cho GJ; Choi WS
    Biochem Biophys Res Commun; 2009 Oct; 388(2):256-60. PubMed ID: 19664600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and evaluation of inhibitors of transthyretin amyloid formation based on the non-steroidal anti-inflammatory drug, flufenamic acid.
    Baures PW; Oza VB; Peterson SA; Kelly JW
    Bioorg Med Chem; 1999 Jul; 7(7):1339-47. PubMed ID: 10465408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of the transthyretin acid denaturation pathways by analytical ultracentrifugation: implications for wild-type, V30M, and L55P amyloid fibril formation.
    Lashuel HA; Lai Z; Kelly JW
    Biochemistry; 1998 Dec; 37(51):17851-64. PubMed ID: 9922152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Methods to evaluate the inhibition of TTR fibrillogenesis induced by small ligands.
    Arsequell G; Planas A
    Curr Med Chem; 2012; 19(15):2343-55. PubMed ID: 22471983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and characterization of potent bivalent amyloidosis inhibitors that bind prior to transthyretin tetramerization.
    Green NS; Palaninathan SK; Sacchettini JC; Kelly JW
    J Am Chem Soc; 2003 Nov; 125(44):13404-14. PubMed ID: 14583036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective binding to transthyretin and tetramer stabilization in serum from patients with familial amyloidotic polyneuropathy by an iodinated diflunisal derivative.
    Almeida MR; Macedo B; Cardoso I; Alves I; Valencia G; Arsequell G; Planas A; Saraiva MJ
    Biochem J; 2004 Jul; 381(Pt 2):351-6. PubMed ID: 15080795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibiting transthyretin amyloid fibril formation via protein stabilization.
    Miroy GJ; Lai Z; Lashuel HA; Peterson SA; Strang C; Kelly JW
    Proc Natl Acad Sci U S A; 1996 Dec; 93(26):15051-6. PubMed ID: 8986762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amyloid fibril composition and transthyretin gene structure in senile systemic amyloidosis.
    Gustavsson A; Jahr H; Tobiassen R; Jacobson DR; Sletten K; Westermark P
    Lab Invest; 1995 Nov; 73(5):703-8. PubMed ID: 7474944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diflunisal stabilizes familial amyloid polyneuropathy-associated transthyretin variant tetramers in serum against dissociation required for amyloidogenesis.
    Tojo K; Sekijima Y; Kelly JW; Ikeda S
    Neurosci Res; 2006 Dec; 56(4):441-9. PubMed ID: 17028027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The most pathogenic transthyretin variant, L55P, forms amyloid fibrils under acidic conditions and protofilaments under physiological conditions.
    Lashuel HA; Wurth C; Woo L; Kelly JW
    Biochemistry; 1999 Oct; 38(41):13560-73. PubMed ID: 10521263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The discovery and development of transthyretin amyloidogenesis inhibitors: what are the lessons?
    Zhong B; Huang X; Zheng Y; Guo X; Wu L
    Future Med Chem; 2021 Dec; 13(23):2083-2105. PubMed ID: 34633220
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential treatment of transthyretin-type amyloidoses by sulfite.
    Altland K; Winter P
    Neurogenetics; 1999 Sep; 2(3):183-8. PubMed ID: 10541593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of lethal and nonlethal transthyretin variants and their relationship to amyloid disease.
    McCutchen SL; Lai Z; Miroy GJ; Kelly JW; Colón W
    Biochemistry; 1995 Oct; 34(41):13527-36. PubMed ID: 7577941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transthyretin quaternary and tertiary structural changes facilitate misassembly into amyloid.
    Kelly JW; Colon W; Lai Z; Lashuel HA; McCulloch J; McCutchen SL; Miroy GJ; Peterson SA
    Adv Protein Chem; 1997; 50():161-81. PubMed ID: 9338081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TTR fibril formation inhibitors: is there a SAR?
    Nencetti S; Orlandini E
    Curr Med Chem; 2012; 19(15):2356-79. PubMed ID: 22471984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and structural analysis of halogen substituted fibril formation inhibitors of Human Transthyretin (TTR).
    Ciccone L; Nencetti S; Rossello A; Stura EA; Orlandini E
    J Enzyme Inhib Med Chem; 2016; 31(sup1):40-51. PubMed ID: 27067161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.